The Phase I Study of HS-10509 in Chinese Adult Subjects

Summary

The study is to evaluate the safety, tolerability, and PK characteristics following single administration of HS-10509 in healthy adults, and multiple administrations of HS-10509 in patients with schizophrenia. Participants will have HS-10509 tablets or placebo once in the single ascending dose (SAD) part or once daily for 28 days in the multiple ascending dose (MAD) part.

Timeline

Start

2024-03

Primary completion

2024-05

Completion

2024-10

Drugs

Indications